Please login to the form below

Not currently logged in
Email:
Password:

VentiRx appoints James Kyle Bryan as chief medical officer

He has more than 20 years of experience in oncology

US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.

This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.

“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”

30th April 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics